Year |
Citation |
Score |
2016 |
Miller EJ, Mays SG, Baillie MT, Howard RB, Culver DG, Saindane M, Pruett ST, Holt JJ, Menaldino DS, Evers TJ, Reddy GP, Arrendale RF, Natchus MG, Petros JA, Liotta DC. Discovery of a Fluorinated Enigmol Analog with Enhanced in Vivo Pharmacokinetic and Anti-Tumor Properties. Acs Medicinal Chemistry Letters. 7: 537-42. PMID 27190606 DOI: 10.1021/Acsmedchemlett.6B00113 |
0.509 |
|
2013 |
Mays SG, Baillie MT, Miller EJ, Bushnev AS, Pruett ST, Culver DG, Evers TJ, Gao J, Reddy GP, Natchus MG, Arrendale RF, Howard RB, Liotta DC, Petros JA. 330 FLUORINATION OF ENIGMOL IMPROVES TISSUE UPTAKE AND AFFECTS
IN VIVO
PROSTATE CANCER EFFICACY Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.1715 |
0.518 |
|
2011 |
Garnier-Amblard EC, Mays SG, Arrendale RF, Baillie MT, Bushnev AS, Culver DG, Evers TJ, Holt JJ, Howard RB, Liebeskind LS, Menaldino DS, Natchus MG, Petros JA, Ramaraju H, Reddy GP, et al. Novel synthesis and biological evaluation of enigmols as therapeutic agents for treating prostate cancer. Acs Medicinal Chemistry Letters. 2: 438-43. PMID 24900327 DOI: 10.1021/Ml2000164 |
0.61 |
|
2011 |
Garnier-Amblard EC, Mays SG, Arrendale RF, Baillie MT, Bushnev AS, Culver DG, Evers TJ, Holt JJ, Howard RB, Liebeskind LS, Menaldino DS, Natchus MG, Petros JA, Ramaraju H, Reddy GP, et al. Novel synthesis and biological evaluation of enigmols as therapeutic agents for treating prostate cancer Acs Medicinal Chemistry Letters. 2: 438-443. DOI: 10.1021/ml2000164 |
0.608 |
|
Show low-probability matches. |